The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?

Ian F Parney; Alberto Malucelli; Michael Gustafson; Allan B Dietz

The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?

Ian F Parney, Alberto Malucelli, Michael Gustafson, Allan B Dietz

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.

Original language	English (US)
Title of host publication	Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome
Publisher	Nova Science Publishers, Inc.
Pages	123-134
Number of pages	12
ISBN (Print)	9781634832892, 9781634832731
State	Published - Jul 1 2015

Keywords

1p/19q
Biomarker
Biopsy
Glioblastoma
IDH
MGMT
Spectroscopy
Texture

ASJC Scopus subject areas

Medicine(all)

Cite this

@inbook{8ffb8527e9874fbc878cf2f38c47961f,

title = "The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?",

abstract = "Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.",

keywords = "1p/19q, Biomarker, Biopsy, Glioblastoma, IDH, MGMT, Spectroscopy, Texture",

author = "Parney, {Ian F} and Alberto Malucelli and Michael Gustafson and Dietz, {Allan B}",

year = "2015",

month = jul,

day = "1",

language = "English (US)",

isbn = "9781634832892",

pages = "123--134",

booktitle = "Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome",

publisher = "Nova Science Publishers, Inc.",

}

TY - CHAP

T1 - The role of biomarkers in glioblastoma diagnosis

T2 - Will tissue diagnosis still be needed?

AU - Parney, Ian F

AU - Malucelli, Alberto

AU - Gustafson, Michael

AU - Dietz, Allan B

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.

AB - Molecular abnormalities in gliomas that carry significant diagnostic, therapeutic, and prognostic implications are increasingly recognized including IDH mutation, 1p/19q chromosome co-deletion, and MGMT promoter methylation. These and other biomarkers can also be increasingly detected by imaging or blood and body fluid analysis. This raises the question of whether tissue diagnosis is still needed in this molecular era. We will review current knowledge of biomarkers in gliomas, non-invasive methods for assessing these biomarkers, and the pros and cons of biomarker assessment vs. tissue diagnosis.

KW - 1p/19q

KW - Biomarker

KW - Biopsy

KW - Glioblastoma

KW - IDH

KW - MGMT

KW - Spectroscopy

KW - Texture

UR - http://www.scopus.com/inward/record.url?scp=84957950529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957950529&partnerID=8YFLogxK

M3 - Chapter

AN - SCOPUS:84957950529

SN - 9781634832892

SN - 9781634832731

SP - 123

EP - 134

BT - Glioblastoma Multiforme: Symptoms, Diagnosis, Therapeutic Management and Outcome

PB - Nova Science Publishers, Inc.

ER -

The role of biomarkers in glioblastoma diagnosis: Will tissue diagnosis still be needed?

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this